Data Dictionary: Pancreatic cancer - DPCA: Difference between revisions
No edit summary |
No edit summary |
||
| Line 84: | Line 84: | ||
'''SARS-CoV-2 Suspected or Confirmed Infection''' | |||
* Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission. | * Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission. | ||
* Date of the first suspicion of SARS-CoV-2 infection. | * Date of the first suspicion of SARS-CoV-2 infection. | ||
| Line 92: | Line 92: | ||
'''Preoperative and Postoperative COVID-19 Testing''' | |||
* Number of preoperative RT-PCR tests and the date of the first test. | * Number of preoperative RT-PCR tests and the date of the first test. | ||
* Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score. | * Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score. | ||
| Line 100: | Line 100: | ||
'''Patient Characteristics''' | |||
* Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste). | * Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste). | ||
* Patient's smoking status and pack-years. | * Patient's smoking status and pack-years. | ||
| Line 106: | Line 106: | ||
'''Surgical and Intensive Care Considerations''' | |||
* Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events). | * Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events). | ||
* Impact on neoadjuvant treatment and changes in treatment plans or schedules. | * Impact on neoadjuvant treatment and changes in treatment plans or schedules. | ||
| Line 113: | Line 113: | ||
'''ICU Admission Related to COVID-19''' | |||
* Presence and type of ICU admission related to COVID-19. | * Presence and type of ICU admission related to COVID-19. | ||
* Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO). | * Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO). | ||
* ICU admission and discharge dates and durations. | * ICU admission and discharge dates and durations. | ||
* Destination after ICU discharge. | * Destination after ICU discharge. | ||
Revision as of 21:34, 8 May 2024
Go back to Dutch Institute for Clinical Auditing Databases (DICA) (The Netherlands) page.
This is a summary of the variables available in the database. You can download the complete data dictionary. [Click here to learn more.
Patient Demographics and Identification:
- Healthcare Institution (Zorginstelling)
- Unique Patient Number (Uniek Patiëntnummer)
- Social Security Number (Burger Service Nummer)
- Surname (Geslachtsnaam)
- Date of Birth (Geboortedatum)
- Gender (Geslacht)
- Country (Country of Residence) (Land (Woonadres))
- Postal Code (Postcode)
- Date of Death (if applicable) (Datum overlijden (indien van toepassing))
Comorbidities:
- Comorbidities, with options to add a new record or update based on changes or previous registrations (Comorbiditeiten)
Medical Procedures:
- Procedures, where multiple procedures per patient can be registered if applicable (Verrichtingen)
COVID-19 Module:
- A generic COVID-19 module added due to the impact of the coronavirus crisis on the quality of care, allowing for the better interpretation of indicators during this period (Deze generieke COVID-19 module)
Pathology Variables through PALGA:
- Pathology variables automatically structured and included in the registration via the PALGA-pathology module, requiring no additional data (In het kader van de PALGA-koppeling worden pathologie variabelen)
Patient Identification and Treatment Timeline
- Treatment start date
- Reason for registration
- Hospital patient number
Patient Physical and Performance Metrics
- Height in cm
- Preoperative weight in kg
- Weight loss in kg and period in weeks
- ECOG performance status (Eastern Cooperative Oncology Group)
Laboratory Biomarkers
- Bilirubine in µmol/l
- Hemoglobine in mmol/l
- Albumine in g/l
- IgG4 in g/l
- Carcinoembryonic antigen (CEA) in µg/l
- CA19.9 in kU/l (Note: Last CA19.9 before the start of neoadjuvant treatment or surgery)
Imaging and Diagnostic Procedures
- CT, MRI, or MRCP performed
- Date of the last preoperative imaging
- Presence of a tumor in the pancreas or periampullary on CT or MRI
- Cystic features suggestive of malignancy
- Involvement of vessels and other structures on imaging
Histology and Cytology
- Preoperative PA number
- Method and date of obtaining the first positive cytology or histology
- Histological and cytological diagnoses
Multidisciplinary Team Consultations and Decisions
- Date of the last MDT (Multidisciplinary Team) discussion before treatment
- Working diagnosis and eligibility for surgical exploration
Treatment and Surgery Details
- Neo-adjuvant/induction treatment type and start date
- Operative details including ASA score, type of resection, and operative complications
- Postoperative pathology including tumor origin, size, and grade
Postoperative Management and Follow-Up
- Palliative treatments including chemotherapy and radiotherapy
- Date of discharge and any readmissions within 30 days
- Adjuvant therapy details and participation in oncological trials
SARS-CoV-2 Suspected or Confirmed Infection
- Presence of a clinical suspicion or test for SARS-CoV-2 infection prior to and up to 30 days post-admission.
- Date of the first suspicion of SARS-CoV-2 infection.
- Date of the first specific test for SARS-CoV-2 infection.
- Date of the first positive laboratory test for SARS-CoV-2.
- Final status regarding SARS-CoV-2 infection.
Preoperative and Postoperative COVID-19 Testing
- Number of preoperative RT-PCR tests and the date of the first test.
- Date of the first preoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
- Number of postoperative RT-PCR tests and the date of the first test.
- Date of the first postoperative CT thorax with COVID-19 concern and CORADS 4-5 score.
- Definitive preoperative and postoperative COVID-19 status.
Patient Characteristics
- Symptoms indicative of COVID-19 (e.g., cough, fever, dyspnea, loss of smell/taste).
- Patient's smoking status and pack-years.
- Patient's height (in cm) and weight (in kg) at admission.
Surgical and Intensive Care Considerations
- Presence of preoperative COVID-19 related complications (e.g., ARDS, acute renal failure, arrhythmias, thromboembolic events).
- Impact on neoadjuvant treatment and changes in treatment plans or schedules.
- Impact on surgical approach (laparoscopic, robotic, open) due to COVID-19.
- Postoperative complaints consistent with COVID-19 and the number of days post-surgery they began.
ICU Admission Related to COVID-19
- Presence and type of ICU admission related to COVID-19.
- Type of respiratory support during ICU stay (e.g., prone ventilation, ECMO).
- ICU admission and discharge dates and durations.
- Destination after ICU discharge.